skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Next generation drug-eluting stents: focus on bioabsorbable platforms and polymers

Review

(3861) Views  (1705) Full article downloads

Authors: Brendan Doyle, David R Holmes Jr

Published Date November 2009 Volume 2009:2 Pages 47 - 55
DOI: http://dx.doi.org/10.2147/MDER.S5617

Brendan Doyle, David R Holmes Jr

Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minnesota, USA

Abstract: The success of drug-eluting stents in preventing restenosis has shifted the focus of new stent development toward enhancing long term safety and efficacy of these devices, while simultaneously eliminating the need for indefinite dual antiplatelet therapy. A technical advance fulfilling these aims would hold tremendous potential to reduce morbidity, mortality and economic costs associated with the percutaneous treatment of coronary artery disease. An attractive approach is the use of bioabsorbable stent designs. These may include stents with different bioabsorbable drugs, bioabsorbable polymers or even bioabsorbable metallic backbones. A device that could achieve excellent acute and long-term results, but disappear completely within months (thereby avoiding the need for prolonged dual antiplatelet therapy), would be a tremendous advance. Too good to be true? We explore here the scientific rationale and prospects for success with this exciting concept.

Keywords: percutaneous coronary intervention, biodegradable, bioabsorbable, polymer, stent








Readers of this article also read:

Advances in drug eluting stents – focus on the Endeavor® zotarolimus stent
Preparation and characterization of gelatin sponge millispheres injectable through microcatheters
Radiolucency below the crown of mandibular horizontal incompletely impacted third molars and acute inflammation in men with diabetes
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Novel antiplatelet agents in the prevention of cardiovascular complications – focus on ticagrelor
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Antiplatelet combinations for prevention of atherothrombotic events
Clinical experience with apixaban in atrial fibrillation: implications of AVERROES
Dabigatran for prophylaxis of thromboembolic events in patients with atrial fibrillation
Outcome of the HORIZONS-AMI trial: bivalirudin enhances long-term survival in patients with ST-elevation myocardial infarction undergoing angioplasty
  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University